Abstract

BackgroundKidney stone formers with family history have a high rate of stone recurrence after kidney stone removal surgery and there is no effective medication available for treatment. It has been shown that hydroxycitric acid (HCA)-the major component of Garcinia cambogia extract, induces dissolution of the calcium oxalate crystal in vitro, suggesting that clinical-grade Garcinia cambogia has the potential to treat calcium oxalate kidney stone. In this study, we used the Drosophila genetic and non-genetic nephrolithiasis model to evaluate the effect of Garcinia cambogia and HCA on the prevention and removal of calcium oxalate stones in vivo. Methods: WT flies were reared in fly food with different concentrations of GCE for one week.The effect of GCE on preventing the formation of calcium oxalate stone was examined. WT and v-ATPase gene knockdown flies were reared in fly food containing 0.3% NaOx for one week, then fed different concentrations of GCE for one week.The effect of GCE on the removal of calcium oxalate stone was examined. Findings: Garcinia cambogia extract efficiently removes calcium oxalate kidney stones from Malpighian tubules in both genetic and non-genetic Drosophila models of nephrolithiasis in vivo. HCA directly dissolves calcium oxalate stones in Drosophila Malpighian tubules ex vivo. Interpretation: Clinical-grade Garcinia cambogia extract removes calcium oxalate kidney stones from Drosophila Malpighian tubules via directly dissolving calcium oxalate stones by HCA. Our study strongly suggests that clinical-grade Garcinia cambogia extract could be used to treat patients with nephrolithiasis in the future. Funding Statement: F.J.Z. was supported by grants from National Key Research Plan (2017YFA0104602) and F.F.H was supported by the National Key Technology Support Program of China (2013BAI09B06 and 2015BAI2B07), the State Key Program of National Natural Science Foundation of China (81430016), the Major International (Regional) Joint Research Project of National Natural Science Foundation of China (81620108003), the Major Scientific and Technological Planning Project of Guangzhou (15020010), and the Guangzhou Clinical Research Center for Chronic Kidney Disease Program (7415695988305). Declaration of Interests: The authors declare that they have no competing interests. Ethics Approval Statement: The authors state: Not applicable

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call